A new market report from DelveInsight projects significant growth in the dementia-related psychosis (DRP) market over the next decade, forecasting a compound annual growth rate (CAGR) of 26.2% between 2026 and 2036. The report attributes this growth to the rising prevalence of dementia, increasing healthcare spending, and a growing pipeline of therapies aimed at addressing psychosis symptoms such as hallucinations and delusions in people living with dementia. In 2025, the DRP market across the United States, Europe, the United Kingdom, and Japan was estimated at approximately USD $690 million, with more than 5 million diagnosed cases reported across these regions.
According to the report, innovation in the treatment landscape is being driven by both approved therapies and emerging drug candidates. Companies including Acadia Pharmaceuticals, Bristol Myers Squibb, Cognition Therapeutics, Johnson & Johnson, and AgeneBio are advancing novel treatments that target a range of neurological pathways. Several therapies currently in clinical development, such as ACP-204 (remlifanserin), COBENFY (xanomeline-trospium chloride), and Zervimesine (CT1812), have the potential to expand treatment options and improve outcomes for people experiencing dementia-related psychosis.
The report also highlights ongoing challenges in the field, including limited approved treatment options and continued reliance on off-label antipsychotic medications. As research advances and new therapies progress through clinical trials, stakeholders are watching closely for innovations that could address unmet needs and reshape the future of dementia-related psychosis care.
Read more about the report and DelveInsight's analysis of the dementia-related psychosis market.
